Grade-dependent Response to Finasteride in Early Prostate Cancer  by Rick, Ferenc G. & Block, Norman L.
EBioMedicine 7 (2016) 13–14
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryGrade-dependent Response to Finasteride in Early Prostate CancerFerenc G. Rick a,b,⁎, Norman L. Block c,d,e
a Veterans Affairs Medical Center, 1201 N.W. 16th Street, Miami, FL 33125, USA
b Department of Urology, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th St, Miami, FL 33199, USA
c Divisions of Hematology/Oncology and Endocrinology, Department of Medicine, University of Miami, Miller School of Medicine, 1800 N.W. 10th Ave, Miami, FL 33126, USA
d Department of Pathology, University of Miami, Miller School of Medicine, 1800 N.W. 10th Ave, Miami, FL 33125, USA
e Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, 1800 N.W. 10th Ave, Miami, FL 33125, USADOI of original article: http://dx.doi.org/10.1016/j.ebio
⁎ Corresponding author at: Research Service (151), V
1201 N.W. 16th Street, Miami, FL 33125, USA.
E-mail address: ferencrick@gmail.com (F.G. Rick).
http://dx.doi.org/10.1016/j.ebiom.2016.04.022
2352-3964/© 2016 The Authors. Published by Elsevier B.Va r t i c l e i n f oArticle history:
Received 16 April 2016
Accepted 16 April 2016
Available online 19 April 2016
score of 5–6) in those receiving dutasteride versus those given a placebo
(19.9% and 25.1%, respectively); similarly, tumors with a high Gleason
score (8–10) were more frequent in the dutasteride-treated group
than in the placebo group. In the Reduction by Dutasteride of Clinical
Progression Events in Expectant Management (REDEEM) trial,
dutasteride was associated with a 38% decrease in the cancer detectionKeywords:
Early prostate cancer
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Androgen-deprivation therapy
5-alpha reductase inhibitorAndrogen deprivation therapy (ADT) of androgen-dependent pros-
tate cancer (PCa), which is still the gold standard treatment, was
based Huggins andHodges' 1941ﬁnding that the growth of PCa cells re-
quires the androgen, testosterone (Rick & Schally, 2015). In addition, an
increasing body of evidence has revealed that the development and pro-
gression of androgen-dependent PCa to castration-resistant prostate
cancer (CRPC) have an intimate association with the androgen–
androgen receptor axis (AR axis) (Knudsen & Scher, 2009). The applica-
tion of AR axis drugs, such as the 5α-reductase inhibitors (5ARI), ﬁnas-
teride and dutasteride, which decrease levels of dihydrotestosterone
(DHT) in order to prevent development or progression of PCa, remains
to be extensively discussed and is controversial (Kosaka et al., 2014).
The concept is driven by the results of two large, randomized,
placebo-controlled trials: the Prostate Cancer Prevention Trial (PCPT)
with ﬁnasteride (Thompson et al., 2003) and the Reduction by
Dutasteride of Prostate Cancer Events (REDUCE) trial (Andriole et al.,
2010). In the PCPT, ﬁnasteride signiﬁcantly reduced the overall risk of
prostate cancer but cancers with high Gleason scores (7–10) were
found in 6.4% of the tumors in the ﬁnasteride group, compared with
only 5.1% of those being found in the placebo group.m.2016.03.047.
eterans Affairs Medical Center,
. This is an open access article underIn a manner analogous to the PCPT trial, the REDUCE trial reported
an overall reduction in the number of PCa patients (with a low Gleason
rate on repeat biopsy at year 3 inmenwith low-gradeGleason score (5–
6) prostate cancer undergoing active surveillance and who received
three years of treatment with dutasteride or placebo (Fleshner et al.,
2012).
Because of concerns regarding the possible induction of de novo ag-
gressive PCa, the US Food and Drug Administration did not grant ap-
proval of 5ARIs for the chemoprevention of PCa in December 2010
(Theoret et al., 2011). However, it is still unclear whether the observed
increase in high-grade CaP in these trials was real or artifact (Lucia et al.,
2007). These observations cannot be fully explained from a purely
mechanistic point of view. Therefore, further basic and clinical investi-
gations are necessary (Kosaka et al., 2014).
In this issue of EBioMedicine, Kim et al. seek to improve biologic un-
derstanding of the grade-speciﬁc effects of the 5ARI, ﬁnasteride, by
studying 183 men with localized prostate cancer, who were random-
ized to receive 5 mg of ﬁnasteride or placebo daily for 4 to 6 weeks
pre-prostatectomy (Kim et al., 2016). In fact, this is one of the few stud-
ies done in early prostate cancer to investigate the time it takes for
changes in gene expression to occur following ﬁnasteride therapy. The
primary end point was to compare the frequency of expression of a
predeﬁned high-grade molecular signature (ERβ, UBE2C, SRD5A2, and
VEGF) differentiating high- and low-grade tumors in the Gleason
grade (GG) 3 areas of ﬁnasteride-exposed tumors with those of
placebo-exposed tumors, adjusted for Gleason score (GS) at prostatec-
tomy. Secondary endpoints included assessment of androgen receptor
(AR) levels, Ki-67, and cleaved caspase 3 to estimate the effects of ﬁnas-
teride on the expression of its downstream targets, cell proliferation,
and apoptosis, respectively. Unfortunately, the primary endpoint could
not be assessed as the predetermined molecular signature was not
able to distinguish GG3 from GG4 areas in the placebo group.
However, expression of AR was signiﬁcantly lower in the GG4 areas
of the ﬁnasteride group compared to those of the placebo group (Kim etthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
14 F.G. Rick, N.L. Block / EBioMedicine 7 (2016) 13–14al., 2016). The authors claim that thisﬁnding is in accordwith an emerg-
ing concept that reduced androgens in prostate tissues may, over time,
lead to de-repression of AR expression, which, in turn, deregulates AR
function and downstream de-repression of the AR target genes normal-
ly suppressed by androgens (Kim et al., 2016). Within the ﬁnasteride
group, AR expression was also lower in GG4 than in GG3 areas, but
not signiﬁcantly.
Expression of the apoptosis marker, cleaved caspase 3, in GG3 and
GG4 tumor areas was signiﬁcantly increased after short-term exposure
to ﬁnasteride, consistentwith preventive efﬁcacy, as shown in the PCPT,
andwas lower in GG4 than in GG3 areaswithin both treatment and pla-
cebo groups (Kim et al., 2016). In the literature, conﬂicting ﬁndings on
the inﬂuence of 5ARIs have been reported, nonetheless, it seems that
the molecular effects of 5ARIs depend on the exposure duration.
One major limitation of this trial is the short period over which the
studywas conducted:molecular alterations in tumors exposed to ﬁnas-
teride may occur over a longer period of time than 4–6 weeks. Another
possible explanation is that the study was underpowered: the original
projections of 100 patients for each group may have been inadequate.
In addition, the evaluation of tumor samples was restricted to the pe-
ripheral zone and to samples with GG patterns primarily presenting
poorly formed and fused glands. It is not known what changes occur
in tumors of transition zone origin or other GG4 patterns.
In summary, this overall well-designed trial by Kimet al. emphasizes
the necessity for further investigation of time-based effects of ﬁnaste-
ride on molecular changes and their basic and clinical importance. Con-
ﬁrmation and extension of these ﬁndings may result in a valuable testallowing the identiﬁcation of ﬁnasteride-responsive tumors in order
to provide personalized care and/or in improved estimates of the risk
of progression of the individual's disease.
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